Since then, the company suffered litigation setbacks on Eylea and Amgen (AMGN) said this week that it had launched a biosimilar version of Eylea 2mg without waiting for the outcome of Regeneron's ...
The 8 mg treatment, administered with a more convenient dosing regimen than Regeneron's (NASDAQ:REGN) blockbuster, 2 mg Eylea, generated $392M in U.S. net sales, which, according to Reuters ...
With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company ...
Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...
Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...
Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...
The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...
Lead drug Eylea has global sales approaching $10 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned ...
Hosted on MSN20d
Regeneron to Report Q3 Earnings: What's in the Offing?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback